{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:08:55Z","timestamp":1783465735106,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.wneu.2019.06.221","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T13:00:45Z","timestamp":1571835645000},"page":"346-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-8776","authenticated-orcid":false,"given":"Fabio","family":"Torregrossa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M'hammed","family":"Aguennouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3918-8798","authenticated-orcid":false,"given":"Domenico","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Sfacteria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2019.06.221_bib1","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1001\/jamaoncol.2016.3806","article-title":"Extent of resection and survival in glioblastoma multiforme","volume":"2","author":"Grasso","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.wneu.2018.12.037","article-title":"Maximizing the extent of resection in high-grade glioma","volume":"123","author":"Grasso","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2019.06.221_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1017926603341","article-title":"Long-term survival in patients with supratentorial glioblastoma","volume":"36","author":"Salvati","year":"1998","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00130404-200305000-00009","article-title":"Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?","volume":"9","author":"Senger","year":"2003","journal-title":"Cancer J"},{"key":"10.1016\/j.wneu.2019.06.221_bib5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/0008-5472.CAN-03-2073","article-title":"Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population","volume":"64","author":"Brat","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib6","first-page":"S3","article-title":"Biology of erythropoietin","volume":"72","author":"Jelkmann","year":"1994","journal-title":"Clin Investig"},{"key":"10.1016\/j.wneu.2019.06.221_bib7","first-page":"724","article-title":"Biology of erythropoietin","volume":"83","author":"Lacombe","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.wneu.2019.06.221_bib8","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood.V94.6.1864","article-title":"Regulation of the erythropoietin gene","volume":"94","author":"Ebert","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2019.06.221_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1006\/smim.1993.1043","article-title":"Signal transduction through the receptor for erythropoietin","volume":"5","author":"Ihle","year":"1993","journal-title":"Semin Immunol"},{"key":"10.1016\/j.wneu.2019.06.221_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1357-2725(99)00071-0","article-title":"The erythropoietin receptor","volume":"31","author":"Tilbrook","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.wneu.2019.06.221_bib11","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/ndt\/gfl769","article-title":"Erythropoietin and its lost receptor","volume":"22","author":"Sturiale","year":"2007","journal-title":"Nephrol Dial Transpl"},{"issue":"suppl 1","key":"10.1016\/j.wneu.2019.06.221_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530150814","article-title":"Jaks and Stats in cytokine signaling","volume":"15","author":"Ihle","year":"1997","journal-title":"Stem Cells"},{"key":"10.1016\/j.wneu.2019.06.221_bib13","doi-asserted-by":"crossref","first-page":"22165","DOI":"10.1074\/jbc.274.32.22165","article-title":"Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines","volume":"274","author":"Silva","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.wneu.2019.06.221_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1432-1033.1995.075_c.x","article-title":"The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells","volume":"234","author":"Gobert","year":"1995","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.wneu.2019.06.221_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/excr.1999.4673","article-title":"Signal transduction in the erythropoietin receptor system","volume":"253","author":"Wojchowski","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib16","doi-asserted-by":"crossref","first-page":"29962","DOI":"10.1016\/S0021-9258(18)43975-0","article-title":"Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor","volume":"269","author":"Miura","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.wneu.2019.06.221_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00008506-200604000-00001","article-title":"Erythropoietin: a new paradigm for neuroprotection","volume":"18","author":"Grasso","year":"2006","journal-title":"J\u00a0Neurosurg Anesthesiol"},{"key":"10.1016\/j.wneu.2019.06.221_bib18","first-page":"565","article-title":"Does administration of recombinant human erythropoietin attenuate the increase of S-100 protein observed in cerebrospinal fluid after experimental subarachnoid hemorrhage?","volume":"96","author":"Grasso","year":"2002","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.06.221_bib19","first-page":"7","article-title":"Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage","volume":"45","author":"Grasso","year":"2001","journal-title":"J\u00a0Neurosurg Sci"},{"key":"10.1016\/j.wneu.2019.06.221_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1073858403259187","article-title":"Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?","volume":"10","author":"Grasso","year":"2004","journal-title":"Neuroscientist"},{"key":"10.1016\/j.wneu.2019.06.221_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3171\/SPI-07\/12\/645","article-title":"Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury: laboratory investigation","volume":"7","author":"Grasso","year":"2007","journal-title":"J\u00a0Neurosurg Spine"},{"key":"10.1016\/j.wneu.2019.06.221_bib22","first-page":"97","article-title":"Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia","volume":"15","author":"Buemi","year":"2002","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.wneu.2019.06.221_bib23","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jtcvs.2018.05.029","article-title":"Neuroprotective role of erythropoietin in spinal cord ischemic injury: where have we been and where are we going?","volume":"156","author":"Grasso","year":"2018","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.wneu.2019.06.221_bib24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00004647-199906000-00007","article-title":"A\u00a0potential role for erythropoietin in focal permanent cerebral ischemia in mice","volume":"19","author":"Bernaudin","year":"1999","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.wneu.2019.06.221_bib25","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1073\/pnas.082097299","article-title":"Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage","volume":"99","author":"Grasso","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2019.06.221_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/2152-7806.198738","article-title":"Management of aneurysmal subarachnoid hemorrhage: state of the art and future perspectives","volume":"8","author":"Grasso","year":"2017","journal-title":"Surg Neurol Int"},{"issue":"suppl 1","key":"10.1016\/j.wneu.2019.06.221_bib27","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/sj.cdd.4401450","article-title":"Erythropoietin as an antiapoptotic, tissue-protective cytokine","volume":"11","author":"Ghezzi","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.wneu.2019.06.221_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0006-8993(02)03239-0","article-title":"Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis","volume":"952","author":"Agnello","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib29","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1523\/JNEUROSCI.4480-05.2006","article-title":"A\u00a0critical role of erythropoietin receptor in neurogenesis and post-stroke recovery","volume":"26","author":"Tsai","year":"2006","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.wneu.2019.06.221_bib30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1432-1033.1996.0494u.x","article-title":"Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA","volume":"239","author":"Yamaji","year":"1996","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.wneu.2019.06.221_bib31","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1073\/pnas.87.15.5978","article-title":"Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells","volume":"87","author":"Anagnostou","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2019.06.221_bib32","doi-asserted-by":"crossref","first-page":"25381","DOI":"10.1074\/jbc.273.39.25381","article-title":"Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis","volume":"273","author":"Yasuda","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.wneu.2019.06.221_bib33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1161::AID-CNCR24>3.0.CO;2-Z","article-title":"Necrosis as a prognostic factor in glioblastoma multiforme","volume":"77","author":"Barker","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2019.06.221_bib34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI115378","article-title":"Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in\u00a0vitro","volume":"88","author":"Mitjavila","year":"1991","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.wneu.2019.06.221_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1523-1755.2000.00211.x","article-title":"Erythropoietin stimulates proliferation of human renal carcinoma cells","volume":"58","author":"Westenfelder","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.wneu.2019.06.221_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V75.3.577.577","article-title":"Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia","volume":"75","author":"Da Silva","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2019.06.221_bib37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1535-7163.1525.3.12","article-title":"Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin","volume":"3","author":"Belenkov","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.wneu.2019.06.221_bib38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/carcin\/bgg060","article-title":"Erythropoietin regulates tumour growth of human malignancies","volume":"24","author":"Yasuda","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.wneu.2019.06.221_bib39","first-page":"6162","article-title":"Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin","volume":"63","author":"Blackwell","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib40","first-page":"395","article-title":"[Erythropoietin accelerates the proliferation of glioma cells via activating Akt pathway]","volume":"38","author":"Liu","year":"2018","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.wneu.2019.06.221_bib41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4103\/njcp.njcp_126_17","article-title":"The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients","volume":"21","author":"Cevik","year":"2018","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.wneu.2019.06.221_bib42","first-page":"3825","article-title":"Local delivery of doxorubicin for the treatment of malignant brain tumors in rats","volume":"25","author":"Lesniak","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib43","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.LAB.0000090156.94795.48","article-title":"Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival","volume":"83","author":"Batra","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.wneu.2019.06.221_bib44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.LAB.0000020415.72863.40","article-title":"Functional significance of erythropoietin receptor expression in breast cancer","volume":"82","author":"Arcasoy","year":"2002","journal-title":"Lab Invest"},{"issue":"suppl 5","key":"10.1016\/j.wneu.2019.06.221_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1634\/theoncologist.9-90005-18","article-title":"The erythropoietin receptor and its expression in tumor cells and other tissues","volume":"9","author":"Farrell","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.wneu.2019.06.221_bib46","first-page":"252","article-title":"Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies","volume":"21","author":"Torp","year":"2002","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.wneu.2019.06.221_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1006233816724","article-title":"Expression of PECAM-1\/CD31 isoforms in human brain gliomas","volume":"43","author":"Aroca","year":"1999","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib48","first-page":"338","article-title":"Survival and invasiveness of astrocytomas promoted by erythropoietin","volume":"106","author":"Mohyeldin","year":"2007","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.06.221_bib49","first-page":"1193","article-title":"Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin","volume":"31","author":"Yin","year":"2007","journal-title":"Int\u00a0J\u00a0Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ijrobp.2008.06.1923","article-title":"Erythropoietin augments survival of glioma cells after radiation and temozolomide","volume":"72","author":"Hassouna","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2019.06.221_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1947601909356352","article-title":"Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance","volume":"1","author":"Cao","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.wneu.2019.06.221_bib52","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.yexcr.2011.06.011","article-title":"Targeting the erythropoietin receptor on glioma cells reduces tumour growth","volume":"317","author":"Peres","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib53","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.18632\/oncotarget.2937","article-title":"Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe","volume":"6","author":"Peres","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2019.06.221_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/bs.vh.2017.03.002","article-title":"Erythropoietin promotes glioblastoma via miR-451 suppression","volume":"105","author":"Alural","year":"2017","journal-title":"Vitam Horm"},{"key":"10.1016\/j.wneu.2019.06.221_bib55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1750-3639.2005.tb00115.x","article-title":"Angiogenesis in gliomas: biology and molecular pathophysiology","volume":"15","author":"Fischer","year":"2005","journal-title":"Brain Pathol"},{"key":"10.1016\/j.wneu.2019.06.221_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10409230091169186","article-title":"Hypoxia, clonal selection, and the role of HIF-1 in tumor progression","volume":"35","author":"Semenza","year":"2000","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.wneu.2019.06.221_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0898-6568(99)00063-7","article-title":"Activation of STAT5 during EPO-directed suppression of apoptosis","volume":"12","author":"Bittorf","year":"2000","journal-title":"Cell Signal"},{"key":"10.1016\/j.wneu.2019.06.221_bib59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.20012","article-title":"Brain and cancer: the protective role of erythropoietin","volume":"25","author":"Buemi","year":"2005","journal-title":"Med Res Rev"},{"key":"10.1016\/j.wneu.2019.06.221_bib60","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib61","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2019.06.221_bib62","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.radonc.2018.02.018","article-title":"DAHANCA 10\u2014effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck: a multicenter, open-label, randomized, phase 3 trial by the Danish Head and Neck Cancer Group","volume":"127","author":"Overgaard","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib65","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.leu.2403246","article-title":"Recombinant human erythropoietin induces intussusceptive microvascular growth in\u00a0vivo","volume":"18","author":"Crivellato","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.wneu.2019.06.221_bib66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1078-0432.CCR-05-1771","article-title":"Erythropoietin biology in cancer","volume":"12","author":"Hardee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12032-007-0037-5","article-title":"Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations","volume":"24","author":"Ahlqvist-Rastad","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib68","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.06.221_bib69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijrobp.2003.12.022","article-title":"Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts","volume":"59","author":"Pinel","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2019.06.221_bib70","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0960-9822(02)00930-2","article-title":"Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts","volume":"12","author":"Dolznig","year":"2002","journal-title":"Curr Biol"},{"key":"10.1016\/j.wneu.2019.06.221_bib71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/jnr.10166","article-title":"Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression","volume":"67","author":"Wen","year":"2002","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.wneu.2019.06.221_bib72","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2015.09.008","article-title":"Erythropoietin stimulates tumor growth via EphB4","volume":"28","author":"Pradeep","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2019.06.221_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.wneu.2019.06.221_bib74","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2019.06.221_bib75","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.athoracsur.2018.05.092","article-title":"Erythropoietin and its double receptors","volume":"107","author":"Grasso","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.wneu.2019.06.221_bib76","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nor102","article-title":"Role of Eph\/ephrin tyrosine kinase in malignant glioma","volume":"13","author":"Nakada","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2019.06.221_bib77","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/bjc.2014.73","article-title":"Eph receptors as therapeutic targets in glioblastoma","volume":"111","author":"Day","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.wneu.2019.06.221_bib78","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.wneu.2019.02.086","article-title":"When neuroprotection becomes a potential ally of high-grade glioma","volume":"125","author":"Grasso","year":"2019","journal-title":"World Neurosurg"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875019318789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875019318789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:31:32Z","timestamp":1761813092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875019318789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":78,"alternative-id":["S1878875019318789"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2019.06.221","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2019.06.221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}